semaglutide and alzheimer's disease Drug maker Novo Nordisk has announced that its weight-loss drug failed to slow down the decline in memory thinking in people with early disease. This disappointing news will come A Systematic Review of Semaglutide's

In addition, among those with a BMI 50.0 seeking bariatric surgery, up to 50% experience recurrent binge-eating episodes (Vinai et al., 2015)

Reported observations include: Localized injection-site reactions such as redness, itching, or mild swelling

GSK announced today that the FDA approved the ibat inhibitor Lynavoy for the treatment of cholestatic pruritus

Tolerance levels increase: Your body may build tolerance for the specific dose of the drug youre taking, and you may need higher and higher doses to continue losing weight

Adherence-related data empowers employers to make informed, nuanced decisions amid evolving pricing models and clinical developments